Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Varicella-zoster virus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44366   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Varicella-zoster virus. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2013-003535-30 Sponsor Protocol Number: 200147 Start Date*: 2015-10-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals’ Varilrix HSA-free varicella vaccine and Varilrix™ given as a 2 dose course in the secon...
    Medical condition: Vaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10069613 Varicella immunisation PT
    19.0 10042613 - Surgical and medical procedures 10069628 Varicella immunization LLT
    19.0 100000004848 10063315 Varicella zoster virus DNA test positive LLT
    19.0 10021881 - Infections and infestations 10046983 Varicella zoster LLT
    19.0 10021881 - Infections and infestations 10046980 Varicella PT
    19.0 100000004858 10050331 Varicella-like rash LLT
    19.0 100000004848 10063144 Varicella zoster virus serology positive LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004442-25 Sponsor Protocol Number: CFAM810B2304 Start Date*: 2016-04-12
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A multicenter, open-label, single-arm, two-step study to evaluate the safety and single-dose pharmacokinetics of famciclovir and multiple-dose safety after administration of famciclovir oral pediat...
    Medical condition: Chickenpox Herpes Zoster
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005825-75 Sponsor Protocol Number: 105909 MeMuRu-OKA 047 Start Date*: 2006-03-20
    Sponsor Name:GLAXO SMITHKLINE
    Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline s GSK Biologicals measles-mumps-rubella-varicella candidate vaccine MeMuRu-OKA and ...
    Medical condition: Active immunisation against mumps, measles, rubella and varicella
    Disease: Version SOC Term Classification Code Term Level
    6.1 10046980 PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002669-19 Sponsor Protocol Number: X04-VAR-402 Start Date*: 2004-12-23
    Sponsor Name:AVENTIS PASTEUR MSD S.P.A.
    Full Title: A double-blind, randomised, controlled, multi-centre safety study of a refrigerator-stable formulation of VARIVAX® in healthy 12 to 15 month-old infants.
    Medical condition: Active immunisation against varicella
    Disease: Version SOC Term Classification Code Term Level
    6.1 10046980 PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001332-22 Sponsor Protocol Number: RG_12-201 Start Date*: 2013-06-20
    Sponsor Name:University of Birmingham
    Full Title: PEPtalk 2: Pilot of a randomised controlled trial to compare VZIG and aciclovir as post-exposure prophylaxis against chickenpox in children with cancer
    Medical condition: Exposure to Varicella by children who have cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10046980 Varicella PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001608-37 Sponsor Protocol Number: 115555MMRV-063 Start Date*: 2011-12-16
    Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS SA
    Full Title: Open, randomised, controlled, multicenter Phase IIIb study to evaluate the immune response and safety, after the administration of GlaxoSmithKline Biologicals live attenuated measles mumps rubell...
    Medical condition: Vaccination of children from the age of 9 months up to 12 years inclusive against measles, mumps, rubella and varicella diseases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10028257 Mumps PT
    14.1 10021881 - Infections and infestations 10046980 Varicella PT
    14.1 10021881 - Infections and infestations 10039252 Rubella PT
    14.1 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-006065-14 Sponsor Protocol Number: 105908 Start Date*: 2006-04-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline's (GSK) Biologicals' measles-mumps-rubella-varicella candidate vaccine (MeMuRu-OKA) and ...
    Medical condition: Healthy male and female children between 15 months and 6 years of age who previously received an MMR vaccine will receive one dose of MMR + V or MMRV. A second dose of varicella vaccine will be giv...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002676-41 Sponsor Protocol Number: 100388,103494,104105,104106 Start Date*: 2005-05-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Blinded, randomised, controlled, multicenter study to evaluate the clinical efficacy against varicella disease of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (Varilrix) given on ...
    Medical condition: Healthy children between 12-22 months (including the day before the 23-month birthday) of age at the time of vaccination with no history of measles, mumps, rubella and varicella diseases/vaccination.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10028257 Mumps PT
    14.1 10021881 - Infections and infestations 10046980 Varicella PT
    14.1 10021881 - Infections and infestations 10039252 Rubella PT
    14.1 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) SK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001910-27 Sponsor Protocol Number: V210-A03 Start Date*: 2019-07-02
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantl...
    Medical condition: Prevention of varicella in individuals 12 months of age and older
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10069628 Varicella immunization LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005319-30 Sponsor Protocol Number: 217917 Start Date*: 2022-11-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow-up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of imm...
    Medical condition: Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    21.1 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    20.1 10021881 - Infections and infestations 10030865 Ophthalmic herpes zoster PT
    20.0 10021881 - Infections and infestations 10063491 Herpes zoster oticus PT
    21.1 10021881 - Infections and infestations 10075611 Varicella zoster virus infection PT
    20.0 10021881 - Infections and infestations 10074297 Herpes zoster cutaneous disseminated PT
    23.1 10021881 - Infections and infestations 10080516 Herpes zoster reactivation PT
    23.1 10021881 - Infections and infestations 10084396 Disseminated varicella zoster virus infection PT
    20.0 10021881 - Infections and infestations 10072210 Genital herpes zoster PT
    20.1 10021881 - Infections and infestations 10061208 Herpes zoster infection neurological PT
    20.0 10021881 - Infections and infestations 10074259 Herpes zoster meningitis PT
    20.0 10021881 - Infections and infestations 10074248 Herpes zoster meningoencephalitis PT
    20.0 10021881 - Infections and infestations 10074243 Varicella zoster oesophagitis PT
    21.1 10021881 - Infections and infestations 10074254 Varicella zoster pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) EE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003652-37 Sponsor Protocol Number: V212-001-00 Start Date*: 2007-03-02
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZ...
    Medical condition: Herpes zoster (HZ).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020150-34 Sponsor Protocol Number: V212-001-01 Start Date*: 2010-10-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet...
    Medical condition: Incidence of Herpes Zoster in recipients of Autologous HCTs
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) SE (Completed) CZ (Completed) GB (Completed) LT (Completed) IT (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000592-27 Sponsor Protocol Number: 13102014 Start Date*: 2015-06-18
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Immunodeficiency in cartilage-hair hypoplasia: sub-project on safety of vaccination against chickenpox
    Medical condition: Cartilage-hair hypoplasia patients.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000744-28 Sponsor Protocol Number: X06-Z-305 Start Date*: 2007-09-21
    Sponsor Name:Sanofi Pasteur MSD S.N.C.
    Full Title: An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX ®, in subjects ≥ 7...
    Medical condition: Herpes zoster [shingles] and post-herpetic neuralgia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006532-66 Sponsor Protocol Number: ZTV02C Start Date*: 2008-03-25
    Sponsor Name:Sanofi Pasteur MSD SNC
    Full Title: An open-label, single-arm, phase IV study assessing the immunogenicity and safety of ZOSTAVAX at minimum release specification approaching expiry potency in subjects ≥50 years old
    Medical condition: Not applicable_Healthy volunteers_Up to 50 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-007235-40 Sponsor Protocol Number: 2008-007235 Start Date*: 2009-06-10
    Sponsor Name:Department für Pädiatrie, Medizinische Universität Innsbruck
    Full Title: Development of Varicella-zoster virus (VZV)-specific CD4+ T cells on primary VZV infection or vaccination in renal transplant (RTX) recipients and healthy donors
    Medical condition: Patients (aged 24 months to 80 years) listed for renal transplantation
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002529-31 Sponsor Protocol Number: VZVAC-TX Start Date*: 2020-08-20
    Sponsor Name:Oslo University Hospital
    Full Title: SAFETY AND EFFICACY OF SHINGRIX VACCINATION IN VARICELLA NAÏVE RENAL TRANSPLANT RECIPIENTS
    Medical condition: Kidney transplant recipients who are varicella-zoster sero-negative. The study aim to evaluate if the Shingrix vaccine will produce immune response in varicella naive kidney transplant recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002313-11 Sponsor Protocol Number: V212-009-00 Start Date*: 2012-01-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease
    Medical condition: Prevention of herpes zoster in adults with autoimmune disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) EE (Completed) DK (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000319-41 Sponsor Protocol Number: RPC01-3101 Start Date*: 2015-09-18
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
    Medical condition: ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) CZ (Completed) NL (Completed) GB (Completed) BE (Completed) BG (Completed) PL (Completed) HR (Completed) LV (Completed) AT (Completed) GR (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000744-34 Sponsor Protocol Number: 204939 Start Date*: 2019-06-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, observer-blind, placebo controlled, multicenter clinical trial to assess Herpes Zoster recurrence and the reactogenicity, safety and immunogenicity of GSK Biologicals’ Herp...
    Medical condition: Healthy volunteers (Prevention of Herpes Zoster)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Dec 19 21:51:10 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA